Cargando…

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO

BACKGROUND: The absence of breast cancer cells in surgical specimens, i.e., pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery characterizes a prognostically heterogeneous group of pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Cosimo, Serena, Ciniselli, Chiara M., Pizzamiglio, Sara, Cappelletti, Vera, Silvestri, Marco, El-Abed, Sarra, Izquierdo, Miguel, Bajji, Mohammed, Nuciforo, Paolo, Huober, Jens, Cameron, David, Chia, Stephen, Gomez, Henry L., Iorio, Marilena V., Vingiani, Andrea, Pruneri, Giancarlo, Verderio, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927225/ https://www.ncbi.nlm.nih.gov/pubmed/36798690 http://dx.doi.org/10.3389/fonc.2022.1028825

Ejemplares similares

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Developing miRNA signatures: a multivariate prospective
por: Verderio, Paolo, et al.
Publicado: (2016)

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
por: Ortolan, E., et al.
Publicado: (2021)

Data and performances evaluation of the SPIDIA-DNA Pan-European External Quality Assessment: 2nd SPIDIA-DNA laboratory report
por: Malentacchi, Francesca, et al.
Publicado: (2016)

Comment on ‘Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'—Methodological challenges in combining miRNAs as circulating biomarkers
por: Verderio, P, et al.
Publicado: (2016)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
por: Silvestri, Marco, et al.
Publicado: (2022)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods
por: Fina, Emanuela, et al.
Publicado: (2017)

FCI: an R-based algorithm for evaluating uncertainty of absolute real-time PCR quantification
por: Verderio, Paolo, et al.
Publicado: (2008)

Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients
por: Fina, Emanuela, et al.
Publicado: (2022)

3Rs Principle and Legislative Decrees to Achieve High Standard of Animal Research
por: Verderio, Paolo, et al.
Publicado: (2023)

Patient-reported outcome measurements in post-mastectomy implant-based breast reconstruction and radiotherapy: Analysis of BREAST-Q data
por: Sala, Laura, et al.
Publicado: (2022)

Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer
por: Reduzzi, Carolina, et al.
Publicado: (2021)

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer
por: Chiodoni, C., et al.
Publicado: (2023)

Biomarkers for Monitoring Pre-Analytical Quality Variation of mRNA in Blood Samples
por: Zhang, Hui, et al.
Publicado: (2014)

SPIDIA-RNA: Second External Quality Assessment for the Pre-Analytical Phase of Blood Samples Used for RNA Based Analyses
por: Malentacchi, Francesca, et al.
Publicado: (2014)

Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread
por: Spreafico, Filippo, et al.
Publicado: (2017)

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
por: Silvestri, Marco, et al.
Publicado: (2023)

Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients
por: Silvestri, Marco, et al.
Publicado: (2021)

The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006)

Multiparametric Analysis of Cell-Free DNA in Melanoma Patients
por: Salvianti, Francesca, et al.
Publicado: (2012)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center
por: Ciniselli, Chiara Maura, et al.
Publicado: (2022)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
por: Capone, Iolanda, et al.
Publicado: (2022)

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
por: Litton, Jennifer K., et al.
Publicado: (2023)

A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis
por: Lecchi, Mara, et al.
Publicado: (2021)

Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended
por: Giussani, Marta, et al.
Publicado: (2021)

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013)

Peritoneal fluid COVID-19 testing in patients with a negative nasopharyngeal swab: prospective study
por: Licata, Armando G, et al.
Publicado: (2023)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
por: Zattarin, Emma, et al.
Publicado: (2020)

Hereditary colorectal cancer syndromes and the COVID-19 pandemic: results from a survey conducted in patients enrolled in a dedicated registry
por: Signoroni, Stefano, et al.
Publicado: (2021)

Neo-Salvarsan
Publicado: (1912)

Cannot write session to /tmp/vufind_sessions/sess_c1kmdkv48tav6ncb4gn43glalu